A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma – Full Text View – ClinicalTrials.gov
The dawn of a new era of control arms, and steroid free regimens!
It is well known that control arms in myeloma have been problematic. Even today there are trials where an “intervention” arm of 3 drugs is being compared to a “control” arm of 2 drugs. But is change is on the horizon? With the advent of promising therapies such as bispecifics in the relapsed/refractory space, there are also exciting trials with “triplet” control arms. The new Phase III trial of teclistamab/daratumumab versus a daratumumab based triplet shines.This is a study where the “intervention arm” is 2 drugs versus a control of 3 drugs. It tells us how confident a sponsor is in their drug, and how they are confident enough to not rely on steroids for additional activity. I look forward to enrolling on this trial, and hope this heralds a new era, with an end to “intervention triplets versus control doublet” trials.
Heres a thread with some additional musings on this matter.
When you believe in your drug, you don’t rely on steroids and take your doublet up against a contemporary triplet 👌🏽👏🏽#mmsm https://t.co/GKhc0AYpUT
— Manni Mohyuddin (@ManniMD1) October 19, 2021
